Literature DB >> 12180477

VAD followed by VMCP: an alternative regimen for multiple myeloma.

Jyoti Wadhwa1, Lalit Kumar, Vinod Kochupillai.   

Abstract

In patients with multiple myeloma, a good complete response rate and disease-free survival may be achieved with sequential chemotherapy using VAD and VMCP, which is an alternative effective and less expensive treatment regimen. This regimen thus assumes particular significance in developing nations like India, where the majority of patients with myeloma cannot afford the cost of high-dose chemotherapy with stem cell rescue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180477     DOI: 10.1385/MO:19:2:105

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  7 in total

1.  VAD-based regimens as primary treatment for multiple myeloma.

Authors:  R Alexanian; B Barlogie; S Tucker
Journal:  Am J Hematol       Date:  1990-02       Impact factor: 10.047

2.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

Review 3.  Multiple myeloma: an update on biology and treatment.

Authors:  H Ludwig; J Meran; N Zojer
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

Review 4.  Intensive treatment strategies in multiple myeloma.

Authors:  T J Kovacsovics; A Delaly
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

5.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

6.  Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

7.  Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.

Authors:  H Ludwig; A M Cohen; A Polliack; H Huber; D Nachbaur; H J Senn; R Morant; S Eckhardt; P Günczler; H L Seewann
Journal:  Ann Oncol       Date:  1995-05       Impact factor: 32.976

  7 in total
  1 in total

1.  Lympho-hemopoietic malignancies in India.

Authors:  Manisha Bhutani; Amish Vora; Lalit Kumar; Vinod Kochupillai
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.